Search Drug Information, Interactions, Images, Dosage & Side Effects

Ondansetron shows potential in irritable bowel syndrome with diarrhoea 27 Mar 2023
A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

VANGUARD sets the stage for a novel biologic in HAE

27 Mar 2023

Dual inhibition of EGFR, VEGF improves progression-free survival in NSCLC

26 Mar 2023

Maternal Crohn’s disease ups risk of infection in offspring

26 Mar 2023

Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma

25 Mar 2023

Higher infliximab concentrations tied to better outcomes in paediatric CD

25 Mar 2023

Sleep loss ups hunger-promoting hormones in adults

25 Mar 2023

Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial

25 Mar 2023

Add-on vistusertib misses mark in platinum-resistant, refractory ovarian high-grade serous carcinoma

25 Mar 2023

Atorvastatin may prevent anthracycline-associated cardiac dysfunction in lymphoma patients

25 Mar 2023

Less salt may be fatally counterproductive for people with heart failure

24 Mar 2023

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure 21 Mar 2023;
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.